Valuation : Mirum Pharmaceuticals, Inc.

Market Cap 6.46B 5.55B 5.23B 4.77B 8.92B 615B 8.96B 61.93B 23.95B 313B 24.26B 23.74B 992B P/E 2026 *
-6.58x
P/E 2027 * -124x
Enterprise Value 6.64B 5.71B 5.38B 4.91B 9.17B 632B 9.21B 63.66B 24.62B 322B 24.94B 24.4B 1,020B EV / Sales 2026 *
9.54x
EV / Sales 2027 * 8.01x
Free-Float
98.34%
Yield 2026 *
-
Yield 2027 * -
1 day-1.24%
1 week-0.04%
Current month+0.25%
1 month-2.33%
3 months+5.04%
6 months+13.90%
Current year+24.45%
1 week 97.01
Extreme 97.01
101.99
1 month 95
Extreme 95
104.66
Current year 73.82
Extreme 73.82
130
1 year 63.23
Extreme 63.232
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Sell

Controller/Auditor

-658 0.0010%
9/1/26 Exercice

Founder

90,000 0.1386%
8/18/26 Exercice

Controller/Auditor

120,000 0.1968%
Change 5-day change 1-year change 3-year change Capi.($)
-1.24%-0.04%+27.02%+230.64% 6.46B
+0.03%-3.09%+52.20%+91.69% 1,002B
-0.76%-1.52%+49.94%+66.34% 649B
+0.86%-3.49%+19.60%+68.37% 440B
-0.80%+0.06%+28.73%+35.45% 346B
-0.13%-14.74%+9.13%+26.71% 263B
-1.90%-2.61%-2.67%+7.41% 250B
-0.48%-10.69%+39.64%+50.82% 213B
-1.06%-1.70%-16.73%-57.36% 201B
-0.68%-2.85%+25.69%+91.64% 182B
Average -0.62%-1.74%+23.25%+61.17% 355.01B
Weighted average by Cap. -0.37%-2.38%+32.36%+57.33%

Financials

2026 *2027 *
Net sales 697M 599M 564M 514M 961M 66.27B 965M 6.68B 2.58B 33.77B 2.61B 2.56B 107B 816M 701M 660M 602M 1.13B 77.62B 1.13B 7.82B 3.02B 39.56B 3.06B 3B 125B
Net income -933M -802M -755M -689M -1.29B -88.76B -1.29B -8.94B -3.46B -45.23B -3.5B -3.43B -143B -32.99M -28.36M -26.7M -24.36M -45.53M -3.14B -45.73M -316M -122M -1.6B -124M -121M -5.06B
Net Debt 181M 156M 146M 134M 250M 17.21B 251M 1.73B 671M 8.77B 679M 665M 27.78B 74.95M 64.42M 60.66M 55.34M 103M 7.13B 104M 718M 278M 3.63B 281M 275M 11.51B
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
433
Date Price Change Volume
26-09-09 US$98.30 -1.24% 511,329
26-09-08 US$99.53 -1.36% 638,466
26-09-04 US$100.90 +0.27% 350,960
26-09-03 US$100.63 +0.80% 453,040
26-09-02 US$99.83 +1.52% 495,626
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
98.30USD
Average target price
138.21USD
Spread / Average Target
+40.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIRM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!